WEBULL
WebtradeDownload

Is DaVita (DVA) Undervalued On Revenue Per Treatment Pressure?

Simply Wall St · 1d ago

DaVita stock reacts to Q2 revenue per treatment setback

DaVita (DVA) drew fresh attention after Q2 results, when a drop in revenue per treatment and ongoing volume and mix headwinds coincided with clear underperformance versus the S&P 500 over the past 3 months.

Over the past year, DaVita has swung from sharp gains to shorter pullbacks, with the share price up strongly year to date. However, the recent 7 day share price return fell 5.53% and the 90 day share price return declined 14.16%, even as the 3 year total shareholder return sits at 91.29%.

Compare DaVita's recent pullback with hand-picked healthcare peers by scanning our 38 healthcare AI stocks for potential treatments-focused opportunities under fresh earnings pressure.

DaVita now trades at a sizeable discount to both analyst targets and some intrinsic value estimates after the post earnings slide. Is that caution well placed given revenue per treatment pressure, or has the pullback already gone too far?

Most Popular Narrative: 17% Undervalued

DaVita's most followed thesis places fair value at $219.86, which sits well above the latest close of $183.14. That gap is anchored to how integrated care and treatment technology might reshape future earnings power.

The Integrated Kidney Care business is achieving the highest aggregate savings in its CMS program with improved quality scores and is expected to add roughly US$20 million of adjusted operating income growth in 2026 and around 1 percentage point of ongoing operating income contribution, which can support DaVita’s earnings even if U.S. dialysis reimbursement remains tight.

See why 20 investors see DaVita as 17% undervalued.

Result: Fair Value of $219.86 (UNDERVALUED)

Still, DaVita faces real pressure if U.S. dialysis reimbursement lags cost trends and payer mix shifts trim revenue per treatment more than analysts currently factor in.

Find out about the key risks to this DaVita narrative.

Next Steps

Sentiment on DaVita is clearly split, with real concerns on one side and credible upside drivers on the other. Investors should move quickly to review both angles and weigh the 3 key rewards and 1 important warning sign.

Looking for more DaVita style investment ideas?

If DaVita has sharpened your focus on quality and pricing power, you can use these targeted stock lists to spot fresh opportunities before they move beyond reach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.